The global drug screening market size is anticipated to reach USD 11.99 billion by 2030 and is growing at a CAGR of 4.0% during the forecast period. The market is driven by increasing workplace safety concerns, regulatory compliance, and requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.
The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021¬ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.
Similarly, the incidence of illegal substance use among Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.
Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, introduced rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring process, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.
The approval of AvertD is part of FDA's broader efforts to address opioid crisis, which includes the introduction of FDA Overdose Prevention Framework in August 2022 and the approval of nonprescription naloxone nasal spray products in March and July 2023. The FDA's commitment to addressing these crisis is evident in its continued support for the development of medical devices that can help assess and mitigate the risk of opioid use disorder.
This product will be delivered within 1-3 business days.
The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021¬ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.
Similarly, the incidence of illegal substance use among Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.
Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, introduced rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring process, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.
The approval of AvertD is part of FDA's broader efforts to address opioid crisis, which includes the introduction of FDA Overdose Prevention Framework in August 2022 and the approval of nonprescription naloxone nasal spray products in March and July 2023. The FDA's commitment to addressing these crisis is evident in its continued support for the development of medical devices that can help assess and mitigate the risk of opioid use disorder.
Drug Screening Market Report Highlights
- Consumables dominated the product type segment with the fastest revenue market share in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to extensive R&D initiatives undertaken by major players to develop kits
- Based on type segment, urine sample dominated the market with the largest revenue share in 2023 attributed to the ease of collection. Urine drug testing is generally more cost-effective compared to other testing methods, such as hair testing
- Drug treatment centers end-use segment dominated the market in 2023, attributed to the increasing focus on substance abuse treatment and rehabilitation, leading to a higher demand for drug testing services in these centers
- North America dominated the global market owing to factors such as advanced healthcare infrastructure, the region’s high consumption of illegal substances, and the necessity for workplace drug tests
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Drug Screening Market Variables, Trends & Scope
Chapter 4. Drug Screening Market: Product Type Estimates & Trend Analysis
Chapter 5. Drug Screening Market: Technology Estimates & Trend Analysis
Chapter 6. Drug Screening Market: End-use Estimates & Trend Analysis
Chapter 7. Drug Screening Market: Regional Estimates & Trend Analysis by Product Type, Sample Type, and End-use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Quest Diagnostics Incorporated
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Siemens Healthcare AG
- Laboratory Corporation of America Holdings
- Alfa Scientific Designs, Inc.,
- OraSure Technologies, Inc.
- Omega Laboratories, Inc.
- Drägerwerk AG & Co. KGaA
- Bio-Rad Laboratories, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | June 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 9.11 Billion |
| Forecasted Market Value ( USD | $ 11.99 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
